Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

Clinical trial NCT04740190 · COMPLETED

Trial details

NCT number: NCT04740190
Sponsor: The University of Hong Kong
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Glioma Recurrent Glioblastoma Poly ADP Ribose Polymerase (PARP) Inhibitor PTEN Gene Inactivation IDH Mutation

Start date: 2021-01-01
Primary completion: 2023-12-14
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.